Based on our assumption that the BTK inhibitor Ib, which can be used in some subsets of Burkitt’s lymphoma, could have a synergistic effect when combined with dEZH2, we tested the combination therapy of Ib with iEZH2 or Ib with dEZH2. The gene discussed is BTK; the disease is Burkitt lymphoma.